RESCUE: Assessing Health and Economic Outcomes William C. Black, M.D. Dartmouth-Hitchcock Medical Center.

Slides:



Advertisements
Similar presentations
Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Advertisements

Emma Frew Introduction to health economics, MSc HEHP, October 2012 Outcomes: part II.
COURAGE Economic Results of the COURAGE Trial William S. Weintraub, MD Chief of Cardiology Christiana Care Health System Professor of Medicine, Thomas.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
Assessing Health and Economic Outcomes for Diagnostic Imaging William C. Black, M.D. Dartmouth-Hitchcock Medical Center.
The role of economic modelling – a brief introduction Francis Ruiz NICE International © NICE 2014.
Economic Analysis and Management Todd Wagner, PhD.
Recommendations for Conducting Cost Effectiveness: Elements of the Reference Case Ciaran S. Phibbs, Ph.D. February 25, 2009.
David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich W. Mohr, Haiyan Li, Yang Lei, Kaijun Wang, Kate Robertus, Elizabeth M. Mahoney, Yueping.
Matthew R. Reynolds, M.D., M.Sc. On Behalf of the PARTNER Investigators Lifetime Cost Effectiveness of Transcatheter Aortic Valve Replacement Compared.
COST–EFFECTIVENESS ANALYSIS AND COST-UTILITY ANALYSIS
The Panel on Cost-Effectiveness in Health and Medicine Marthe Gold City University of London 30 October, 2003.
AGEC 608 Lecture 17, p. 1 AGEC 608: Lecture 17 Objective: Review the main aspects of cost- effectiveness analysis (CEA) and cost-utility analysis (CUA).
Ilana F. Gareen, Ph.D. Brown University Center for Statistical Sciences
Health Economics & Policy 3 rd Edition James W. Henderson Chapter 4 Economic Evaluation in Health Care.
Cost Effectiveness of CT Screening in the National Lung Screening Trial William C. Black, M.D. Dartmouth-Hitchcock Medical Center NLST CEA Writing Team.
Assessing Health and Economic Outcomes William C. Black, M.D. Director ACRIN Outcomes & Economics Core Laboratory Dartmouth-Hitchcock Medical Center.
1 Health-Related Quality of Life Ron D. Hays, Ph.D. - UCLA Department of Medicine: Division of General Internal Medicine.
MAPPING THE DIABETES HEALTH PROFILE (DHP-18) ONTO THE EQ-5D AND SF-6D GENERIC PREFERENCE BASED MEASURES OF HEALTH Brendan Mulhern 1, Keith Meadows 2, Donna.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Introduction to Effectiveness, Patient Preferences and Utilities Patsi Sinnott, PT, PhD, MPH HERC Economics Course May 6, 2009.
Terry Field, D.Sc. Meyers Primary Care Institute University of Massachusetts Medical School, Fallon Community Health Plan, Fallon Clinic.
Economics of Implementation: Moving beyond Traditional CEA Mark Smith Paul Barnett VA Health Economics Resource Center.
TACTICS-TIMI 18 Economics & HRQOL Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy.
These slides were released by the speaker for internal use by Novartis.
2011 ACRIN Annual Meeting Cost-Effectiveness of Screening in the National Lung Screening Trial William C. Black, MD Dartmouth-Hitchcock Medical Center.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 11: Cost-utility analysis – Part 4.
Measuring Health Outcomes
Types of analysis. Simulation rationale u Each patient’s natural history is random, but guided by underlying parameters. u With sufficiently large number.
IAS July The Development of AntiRetroviral Therapy in Africa (DART) trial Cost Effectiveness Analysis of Routine Laboratory or Clinically Driven.
Cost-Effectiveness of Palliative Team Care For Patients Nearing End-Of-Life Society for Medical Decision Making 36 st Annual Meeting – Miami, Florida October.
Cost-effectiveness of psychotherapy for personality disorders Djøra Soeteman Viersprong Institute for Studies on Personality Disorders Erasmus Medical.
Basic Economic Analysis David Epstein, Centre for Health Economics, York.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 19: Economic Evaluation using Patient-Level.
انواع ارزيابي های اقتصادي سيدرضا مجدزاده مرکز تحقيقات بهره برداری از دانش سلامت و دانشکده بهداشت دانشگاه علوم پزشکي و خدمات بهداشتي درماني تهران.
Economic Analysis: ALLHAT Antihypertensive Trial Paul Heidenreich MD, MS ALLHAT.
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
{ Challenges in cost-utility analysis in the critical care setting Ville Pettilä MD, PhD, A/P Helsinki University Hospital VP SFAI- veckan.
ALLHAT Cost-effectiveness in the ALLHAT Antihypertensive Trial Heidenreich P A, et al. J Gen Intern Med 23(5):509–16.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
Budget Impact Analysis: Methods & Data Mark W. Smith, PhD VA HSR&D Health Economics Resource Center 795 Willow Road (152 MPD), Menlo Park, CA
The Bypassing the Blues Trial Telephone-Delivered Collaborative Care for Treating Post-CABG Depression BL Rollman, B Herbeck Belnap, PR Houck, S Mazumdar,
EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with RA, Non-Inflammatory Disorders (NIRD), and Fibromyalgia (FM)
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Cost-Effectiveness and Outcomes Research Setting value to what we do.
● The results of this study suggest that using the prognostic test to guide ACT decisions in NSCLC is cost-effective compared to a SoC approach according.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 7: Cost-effectiveness analysis – Part.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Cost-Effectiveness of C-Reactive Protein Testing.
Rima Styra, MD, Med Associate Professor of Psychiatry University Health Network Toronto.
Occluded Artery Trial: 1° Hypothesis and Design 1° Hypothesis: Late PCI to open occluded IRA will ↓ death/reinfarction/class IV CHF by 25% compared to.
‘PhysioDirect’ for patients with MSK problems ECONOMIC MODEL OVERVIEW.
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
Introduction Out-of-hospital cardiac arrest (OHCA) is the sudden cessation of the heart in an out of hospital setting. In the United States, the incidence.
Volume 18, Issue 2, Pages (March 2015)
New Medicare Codes OUTPATIENT Billing Code Location of Care Definition
How to Perform a Cost-Effectiveness Analysis
Patient Baseline Assessment
From: Case-Finding Instruments for Depression in Primary Care Settings
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
SYNTAX at 2 Years: This Interventionalist’s Perspective
New Medicare Codes OUTPATIENT Billing Code Location of Care Definition
Cost-Effectiveness of Helicopter Versus Ground Emergency Medical Services for Trauma Scene Transport in the United States  M. Kit Delgado, MD, MS, Kristan.
Financial Disclosures
Laila Hellgren, MD, Elisabeth Ståhle, MD, PhD 
Correlations between observed patient-reported outcomes and disease activity scores at week 24. Correlations between observed patient-reported outcomes.
Measuring outcomes Emma Frew October 2012.
Cost-effectiveness acceptability frontier for three risk-assessment strategies related to pressure-injury prevention best practices from a US societal.
Diabetic Retinopathy Clinical Research Network
Presentation transcript:

RESCUE: Assessing Health and Economic Outcomes William C. Black, M.D. Dartmouth-Hitchcock Medical Center

Outline Health outcomes Economic outcomes CEA

Health Outcomes MACE/ Revacularization Life years (Vital Status) QALYs BL, 12 mos Angina Status

Life Years All observed deaths thru trial All projected deaths after trial Framingham survival estimates based on age, sex, and CV events

Measure of patient utility Measured on a scale of Can be assessed directly or derived, SG vs SF-36 Quality Adjusted Life Year

Standard Gamble

Quality Adjusted Life Years Quantity of Life Quality of Life QALY = = 0.75

QALYs

Derived from BL, 1 yr SS-6D utility scoring Adjusted for age after trial

SF-6D 1.Physical functioning 2.Role limitations 3.Social functioning 4.Pain 5.Mental health 6.Vitality

SF-6D Utility Scoring Physical Functioning TermScore PF PF PF PF PF PF U = ∑Score – Brazier et al. J Health Econ 2002;21:

QoL - Angina BL, 6, 12, 18, & 24 mos BL, 12 mos Not “preference” based

Economic Outcomes Direct cardiac* inpatient care outpatient care medications Indirect cardiac* time and travel

Economic Outcomes Based on 201x dollars Adjusted for timing w MC CPI Projected by age beyond trial

Hospitalization Costs Triggered by patient questionnaire DRGs and CPTs coded by MRA Medicare reimbursement Part A MEDPAR Part B Physician Fee Schedule

Outpatient Costs Triggered by patient questionnaire CPTs coded by MRA Medicare Physician Fee Schedule Red Book avg wholesale prices

Indirect Costs Triggered by patient questionnaire Travel and other expenses Time from usual activities

CEA Societal perspective In-trial and lifetime horizons 3% Sensitivity analysis

Base Case StrategyCostQALYs  Cost  QALYs ICER SPECTNA CCTA

c e III ? Cost-Effective III ? Not Cost-Effective IV Black. Med Decis Making (3):

c e IIIB IV IIIA IA IIIB K Black. Med Decis Making (3):

Uncertainty Sensitivity analysis Scatterplot of ICE CE Acceptability curves

Sensitivity Analysis  LE  QALE Costs In-trial Beyond-trial

Weintraub, W. S. et al. Circ Cardiovasc Qual Outcomes 2008;1:12-20

Bootstrap Method 1.Sample n CTA subjects, compute C* CT, E* CT 2.Sample m SPE subjects, compute C* SP, E* SP 3.Plot ICE: (C* CT – C* SP, E* CT - E* SP ) 4.Repeat steps 1-3 N times * mean

Fenwick et al. BMC Health Serv Res 2006;6:52.